Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.
Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.
复制标题
DOI：
10.1002/hep.31684
复制
发表时间：
2021-08
期刊：
影响因子：
--
通讯作者：
Baumert TF
中科院分区：
文献类型：
--
作者：
Saviano A;Wrensch F;Ghany MG;Baumert TF
2019年底出现的新型冠状病毒--严重急性呼吸系统综合征冠状病毒2型（SARS-CoV-2）感染对全球卫生构成了前所未有的挑战。2019冠状病毒病（COVID-19）是由SARS-CoV-2引起的临床疾病，其表现形式多样，从无症状感染到危及生命的急性呼吸窘迫综合征和多器官衰竭。肝脏受累在COVID-19期间很常见，并表现出从肝功能检查无症状升高到肝功能失代偿的一系列临床表现。肝脏检查异常的存在与COVID-19疾病的更严重表现和总体死亡率相关。尽管在COVID-19患者的肝脏中检测到了SARS-CoV-2 RNA，但目前尚不清楚SARS-CoV-2是否能在肝细胞中有效感染和复制，并具有直接的肝致病作用。COVID-19肝损伤的原因可归因于多种因素，包括病毒诱导的全身性炎症、缺氧、肝充血和药物诱导的肝病。在肝硬化患者中，COVID-19与肝功能失代偿和肝脏相关死亡率相关。此外，COVID-19对医疗资源的影响可能会对慢性肝病患者的护理和结果产生不利影响。了解COVID-19期间肝损伤的潜在机制对于COVID-19患者的管理非常重要，特别是那些患有晚期肝病的患者。这篇综述总结了我们目前对SARS-CoV-2病毒-宿主在肝脏中相互作用的认识，以及肝病对COVID-19的临床影响。
Infection with the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), a novel coronavirus that emerged in late 2019, is posing an unprecedented challenge to global health. Coronavirus disease 2019 (COVID‐19), the clinical disease caused by SARS‐CoV‐2, has a variable presentation ranging from asymptomatic infection to life‐threatening acute respiratory distress syndrome and multiorgan failure. Liver involvement is common during COVID‐19 and exhibits a spectrum of clinical manifestations from asymptomatic elevations of liver function tests to hepatic decompensation. The presence of abnormal liver tests has been associated with a more severe presentation of COVID‐19 disease and overall mortality. Although SARS‐CoV‐2 RNA has been detected in the liver of patients with COVID‐19, it remains unclear whether SARS‐CoV‐2 productively infects and replicates in liver cells and has a direct liver‐pathogenic effect. The cause of liver injury in COVID‐19 can be attributed to multiple factors, including virus‐induced systemic inflammation, hypoxia, hepatic congestion, and drug‐induced liver disease. Among patients with cirrhosis, COVID‐19 has been associated with hepatic decompensation and liver‐related mortality. Additionally, COVID‐19’s impact on health care resources can adversely affect delivery of care and outcomes of patients with chronic liver disease. Understanding the underlying mechanisms of liver injury during COVID‐19 will be important in the management of patients with COVID‐19, especially those with advanced liver disease. This review summarizes our current knowledge of SARS‐CoV‐2 virus‐host interactions in the liver as well the clinical impact of liver disease in COVID‐19.
登录
查看更多内容
DOI：
10.1126/science.abd3072
发表时间：
2020-11-13
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Daly JL;Simonetti B;Klein K;Chen KE;Williamson MK;Antón-Plágaro C;Shoemark DK;Simón-Gracia L;Bauer M;Hollandi R;Greber UF;Horvath P;Sessions RB;Helenius A;Hiscox JA;Teesalu T;Matthews DA;Davidson AD;Collins BM;Cullen PJ;Yamauchi Y
通讯作者：
Yamauchi Y
影响因子：
25.7
作者：
Blach, Sarah;Kondili, Loreta A.;Craxi, Antonio
通讯作者：
Craxi, Antonio
影响因子：
13.5
作者：
Chau, TN;Lee, KC;Lai, CL
通讯作者：
Lai, CL
影响因子：
13.5
作者：
Da, Ben L.;Im, Gene Y.;Schiano, Thomas D.
通讯作者：
Schiano, Thomas D.
影响因子：
2.5
作者：
Chen, Liping;Huang, Shaoping;Cheng, Jilin
通讯作者：
Cheng, Jilin